SVRA - Savara Inc

2.6
-0.150   -5.769%

Share volume: 933,179
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$2.75
-0.15
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.77%
1 Month
-2.26%
3 Months
-6.47%
6 Months
-28.77%
1 Year
-46.94%
2 Year
51.16%
Key data
Stock price
$2.60
P/E Ratio 
0.00
DAY RANGE
$2.56 - $2.84
EPS 
-$0.53
52 WEEK RANGE
$2.26 - $5.34
52 WEEK CHANGE
-$45.15
MARKET CAP 
526.870 M
YIELD 
N/A
SHARES OUTSTANDING 
164.601 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,155,424
AVERAGE 30 VOLUME 
$1,372,668
Company detail
CEO: Matthew Pauls
Region: US
Website: savarapharma.com
Employees: 20
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Savara Inc. focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor. The company is headquartered in Austin, Texas.

Recent news
loading